{"id":11428,"date":"2024-05-28T11:28:15","date_gmt":"2024-05-28T10:28:15","guid":{"rendered":"https:\/\/www.thervacb.eu\/?p=11428"},"modified":"2025-06-16T10:41:39","modified_gmt":"2025-06-16T09:41:39","slug":"ip-cure-b-thervacb-workshop-no2","status":"publish","type":"post","link":"https:\/\/www.thervacb.eu\/ca\/ip-cure-b-thervacb-workshop-no2\/","title":{"rendered":"Researchers from \u201cIP-cure-B\u201d & \u201cTherVacB\u201d continue the dialogue to advance elimination of chronic hepatitis B"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.25.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n

Researchers from the two EC-funded projects\u00a0 \u2018IP-cure-B \u2013 Take care of your health\u2019<\/a> and \u2018TherVacB – A therapeutic vaccine to cure Hepatitis B\u2019 <\/a>continue their collaboration to jointly tackle some of the major challenges in the therapy of viral hepatitis.<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.25.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n

Building on a first exploratory session in summer 2023, a wider team of researchers are meeting on 5th<\/sup> June 2024 for a 2nd<\/sup> round of strategic discussions. The workshop is hosted by both consortia at the Congress of the European Association for the Study of the Liver (EASL) 2024 in Milano, Italy,<\/a> and held at the Milano Convention Centre \u201cAllianz MiCo\u201d in the South Wing Level 2 meeting room \u201cAmber 6\u201d.\u00a0<\/p>\n

<\/h3>\n

[\/et_pb_text][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#ce2525″ custom_padding=”30px|30px|30px|30px|true|true” global_colors_info=”{}”]<\/p>\n

Different approaches, a common goal
<\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n

In 2020, work on chronic hepatitis B by the research and clinical communities in the two projects had kicked-off in parallel. Funded by the European Commission under the same topic<\/a>, both research teams have adopted stratified host-directed approaches to raise awareness and improve prevention, treatment and functional cure of hepatitis B.\u00a0\u00a0<\/p>\n

[\/et_pb_text][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#ce2525″ custom_padding=”30px|30px|30px|30px|true|true” global_colors_info=”{}”]<\/p>\n

Focussed strategy discussions to create synergies<\/strong><\/strong><\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px|||||” global_colors_info=”{}”]<\/p>\n

At EASL 2024, a larger group of IP-cure-B<\/a> and TherVacB experts<\/a> in virology, immunology and clinical hepatitis will engage in focused discussions on the different aspects of viral hepatitis B infection (HBV) and the HBV-mediated chronic disease that they are investigating to reduce the global health burden:\u00a0<\/p>\n